Stockscreener 앱 받기
1.94
8.99%
0.16
전일 마감가:
$1.78
열려 있는:
$1.815
하루 거래량:
4.38M
Relative Volume:
1.21
시가총액:
$72.60M
수익:
-
순이익/손실:
$-57.91M
주가수익비율:
-1.3866
EPS:
-1.3991
순현금흐름:
$-38.14M
1주 성능:
-8.92%
1개월 성능:
-85.96%
6개월 성능:
-83.77%
1년 성능:
-67.67%
1일 변동 폭
$1.80
$1.955
1주일 범위
$1.7301
$2.11
52주 변동 폭
$1.31
$19.40
Tenax Therapeutics Inc Stock (TENX) Company Profile
명칭
Tenax Therapeutics Inc
전화
919-855-2100
주소
101 GLEN LENNOX DRIVE, CHAPEL HILL, NC
Compare TENX vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TENX
Tenax Therapeutics Inc
|
1.94 | 66.61M | 0 | -57.91M | -38.14M | -1.3991 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tenax Therapeutics Inc Stock (TENX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-09-08 | 개시 | Piper Sandler | Overweight |
| 2024-10-24 | 개시 | Leerink Partners | Outperform |
| 2024-10-14 | 개시 | Guggenheim | Buy |
| 2024-09-30 | 개시 | William Blair | Outperform |
| 2017-05-18 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2014-12-16 | 개시 | MLV & Co | Buy |
| 2014-11-18 | 개시 | WallachBeth | Buy |
모두보기
Tenax Therapeutics Inc 주식(TENX)의 최신 뉴스
Price to book forward of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
Enterprise value of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
Total revenue of Tenax Therapeutics, Inc. – HAM:YBO0 - TradingView
RTW Investments, LP Expands Tenax Therapeutics (TENX) Stake Desp - GuruFocus
Tenax Therapeutics (TENX) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Israel Englander funds hold over 5% of Tenax Therapeutics (TENX) - Stock Titan
TENX Q2 2026 Earnings: Narrower Loss Per Share Fails to Offset Stock DeclineEPS Revision Trend - vinanet.vn
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Tenax Therapeutics (TENX) - GlobeNewswire
TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law - The AI Journal
Price-Driven Insight from (TENX) for Rule-Based Strategy - Stock Traders Daily
symbol__ Stock Quote Price and Forecast - CNN
Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Ikarian Capital (TENX) discloses 2.9% beneficial stake in Tenax Therapeutics common stock - Stock Titan
Venrock group (TENX) discloses 1.57M-share warrant-based stake in Tenax - Stock Titan
Perceptive Advisors (TENX) reports beneficial ownership of 1.7M Tenax Therapeutics shares - Stock Titan
Tenax Therapeutics Inc (NASDAQ: TENX) Share Price, TENX Stock News, TENX Share Price & Updates - Kalkine
Tenax Therapeutics (TENX) holder BVF reports 3.11M shares, big warrant overhang - Stock Titan
Vivo Opportunity discloses 9% Tenax Therapeutics (TENX) holding via stock and warrants - Stock Titan
TENX Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Tenax Therapeutics (TENX) - Business Wire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
RTW Investments discloses 9.99% Tenax Therapeutics (TENX) position with 2.87M shares - Stock Titan
Tenax Therapeutics (TENX) Rallies 6.4% to $1.83, Approaching Key ResistanceNarrow Range Breakout - Vinanet
TENX SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Tenax Therapeutics - Morningstar
Piper Sandler Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
Tenax Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Tenax Therapeutics (TENX) - Morningstar
Adage Capital discloses 6.81% Tenax Therapeutics (TENX) stake via stock and warrants - Stock Titan
Tenax Therapeutics Is Maintained at Buy by Canaccord Genuity - Moomoo
Tenax Therapeutics downgraded to Neutral after ... - Pluang
Tenax Stock Plunges 89% After PH-HFpEF Trial Misses Main Goal, But Subgroup Data Offers Hope - finance.biggo.com
TENX Downgraded by Chardan Capital -- Price Target Lowered to $5 - GuruFocus
CCORF Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Tenax Therapeutics (NASDAQ:TENX) Rating Lowered to Neutral at Chardan Capital - MarketBeat
TENX Maintained by Guggenheim -- Price Target Lowered to $4.00 - GuruFocus
TENX Downgraded by Evercore ISI Group -- Price Target Lowered to $5.00 - GuruFocus
Tenax Therapeutics (NASDAQ:TENX) Downgraded by Evercore to "In-Line" - MarketBeat
A Quick Look at Today's Ratings for Tenax Therapeutics(TENX.US), With a Forecast Between $4 to $4 - Moomoo
Leerink Partners Maintains Tenax Therapeutics(TENX.US) With Buy Rating, Announces Target Price $4 - Moomoo
Guggenheim cuts Tenax Therapeutics price target to $4 on trial miss - Investing.com South Africa
TENAX THERAPEUTICS INC : WILLIAM BLAIR CUTS TO MARKET PERFORM RATING - Bitget
Evercore ISI Downgrades Tenax Therapeutics to In Line From Outperform, Adjusts PT to $5 From $39 - marketscreener.com
Tenax Therapeutics’ stock crashes on Phase III trial failure - Yahoo Finance
We're Not Very Worried About Tenax Therapeutics' (NASDAQ:TENX) Cash Burn Rate - simplywall.st
TENAX THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $4 FROM $26 - Bitget
Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF PatientsSlideshow (NASDAQ:TENX) 2026-08-11 - Seeking Alpha
Tenax LEVEL Trial Misses Primary Goal, but Subgroup Data Bolsters Levosimendan Case - MarketBeat
Tenax Therapeutics (TENX) Stock Crashed: Here Is Why - top1markets.com
TENAX THERAPEUTICS INC : CANACCORD GENUITY CUTS TARGET PRICE TO $4 FROM $35 - Bitget
Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson Fistel Investigates Potential Securities Law Violations After Phase 3 Trial Failure; Shares Plummet Nearly 90% - lincolnjournal.com
Tenax Therapeutics, Inc. (NASDAQ: TENX) Investors: Johnson - GlobeNewswire
Tenax Therapeutics (NASDAQ:TENX) Sets New 52-Week LowHere's Why - MarketBeat
William Blair downgrades Tenax Therapeutics stock rating on trial results By Investing.com - Investing.com UK
Tenax Therapeutics Inc (TENX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tenax Therapeutics Inc 주식 (TENX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 02 '26 |
Buy |
1.80 |
187,704 |
337,586 |
5,624,151 |
| ADAR1 Capital Management, LLC | 10% Owner |
Sep 01 '26 |
Buy |
1.80 |
179,058 |
321,570 |
5,436,447 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 21 '26 |
Buy |
1.77 |
716,369 |
1,266,254 |
4,746,444 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 20 '26 |
Buy |
1.78 |
202,124 |
359,538 |
4,030,075 |
| ADAR1 Capital Management, LLC | 10% Owner |
Aug 24 '26 |
Buy |
1.75 |
107,374 |
188,355 |
4,853,818 |
| Giordano Christopher Thomas | CEO |
Jul 13 '26 |
Option Exercise |
5.88 |
8,719 |
51,267 |
11,324 |
| Rich Stuart | Chief Medical Officer |
Dec 09 '25 |
Buy |
10.22 |
2,500 |
25,542 |
5,266 |
| Rich Stuart | Chief Medical Officer |
Dec 08 '25 |
Buy |
10.10 |
2,500 |
25,250 |
5,000 |
| Rich Stuart | Chief Medical Officer |
Dec 04 '25 |
Buy |
9.20 |
2,500 |
22,998 |
2,500 |
| Rich Stuart | Chief Medical Officer |
Dec 03 '25 |
Buy |
9.08 |
1,500 |
13,618 |
2,766 |
0.86%
0.31%
자본화:
|
볼륨(24시간):